Oral extended-release oxymorphone: A new choice for chronic pain relief

A. K. Matsumoto

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Opana® ER (oxymorphone extended release [ER]) is a new oral long-acting formulation indicated for the treatment of moderate to severe chronic pain. Because the ER matrix slowly releases oxymorphone over 12 h, consistent plasma levels are produced with low peak-to-trough fluctuations. Oxymorphone ER is the only long-acting opioid that contains oxymorphone, which exhibits some distinct pharmacologic properties compared with most other opioids, including a longer half-life, higher affinity for the μ-opioid receptor, and lack of interaction with the CYPP450 drug-metabolizing system. With a safety and tolerability profile similar to other opioids and documented efficacy in several models of chronic pain (low back, cancer, and osteoarthritis), oxymorphone ER provides a new option for clinicians and patients in the treatment of chronic pain.

Original languageEnglish (US)
Pages (from-to)1515-1527
Number of pages13
JournalExpert opinion on pharmacotherapy
Issue number10
StatePublished - Jul 2007


  • Analgesia
  • Chronic pain
  • Opioids
  • Oxymorphone

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Oral extended-release oxymorphone: A new choice for chronic pain relief'. Together they form a unique fingerprint.

Cite this